natgillin/translations-raw huggingface dataset:
Eliquis has no or negligible influence on the ability to drive and use machines.
Zdravilo Eliquis nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Eliquis is a medicine that contains the active substance apixaban.
Eliquis je zdravilo, ki vsebuje zdravilno učinkovino apiksaban.
Eliquis is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).
Pri bolnikih z boleznijo jeter, ki je povezana z motnjami strjevanja krvi in s klinično pomembnim tveganjem za krvavitve, je uporaba zdravila Eliquis kontraindicirana (glejte poglavje 4.3).
Eliquis is used to prevent venous thromboembolism (blood clots in the veins) in adults following a hip or knee replacement operation.
Zdravilo Eliquis se uporablja za preprečevanje venske tromboembolije (nastajanja krvnih strdkov v venah) pri odraslih po operativni vstavitvi umetnega kolena ali kolka.
Eliquis may increase the risk of bleeding.
Zdravilo lahko poveča tveganje za krvavitve.
Eliquis must not be used in patients who are actively bleeding, or who have liver disease which leads to problems with blood clotting and an increased risk of bleeding.
Zdravilo Eliquis se ne sme uporabljati pri bolnikih, ki aktivno krvavijo ali imajo obolenje jeter, kar lahko povzroči zaplete s strjevanjem krvi in povečano tveganje za krvavitve.
Eliquis should be used with caution when coadministered with NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk.
Pri sočasni uporabi zdravila Eliquis in nesteroidnih protivnetnih zdravil (vključno z acetilsalicilno kislino) je potrebna previdnost, saj je za ta zdravila značilno, da povečajo tveganje za krvavitve.
Eliquis was also effective at treating deep vein thrombosis and pulmonary embolism and preventing their reoccurrence: in the treatment study, 2.3% of patients treated with Eliquis had a clotting event or died, compared with 2.7% of patients treated with enoxaparin plus warfarin, showing that Eliquis was as effective as the comparator treatment.
Zdravilo Eliquis je bilo učinkovito tudi pri zdravljenju globoke venske tromboze in pljučne embolije ter pri preprečevanju njunega ponovnega pojava: v študiji o zdravljenju so strdek ali smrt zabeležili pri 2,3 % bolnikov, ki so jih zdravili z zdravilom Eliquis, v primerjavi z 2,7 % bolnikov, ki so jih zdravili z enoksaparinom in varfarinom, kar kaže, da je bilo zdravilo Eliquis prav tako učinkovito kot primerjalno zdravljenje.
Eliquis was also shown to be effective in preventing strokes and arterial blood clots in patients with atrial fibrillation.
Zdravilo Eliquis se je izkazalo za učinkovito tudi pri preprečevanju kapi in arterijskih krvnih strdkov pri bolnikih z atrijsko fibrilacijo.
Eliquis was effective at preventing blood clots in the veins following a hip or knee replacement.
Zdravilo Eliquis je bilo učinkovito pri preprečevanju nastajanja krvnih strdkov po operativni vstavitvi umetnega kolka ali kolena.
Eliquis will be used with caution in patients with signs of altered liver function.
Pri bolnikih z znaki spremenjenega delovanja jeter je treba zdravilo Eliquis uporabljati previdno.
ellaOne can be taken at any time during the menstrual cycle.
Zdravilo ellaOne se lahko zaužije kadar koli med menstrualnim ciklusom.
ellaOne contains lactose
Zdravilo ellaOne vsebuje laktozo
ellaOne does not interrupt an existing pregnancy.
Zdravilo ellaOne ne prekine obstoječe nosečnosti.
ellaOne does not prevent pregnancy in every case.
Zdravilo ellaOne ne prepreči nosečnosti v vsakem primeru.
ellaOne inhibits or postpones ovulation (see section 5.1).
Zdravilo ellaOne zavre ali odloži ovulacijo (glejte poglavje 5.1).
ellaOne is a contraceptive used to prevent a pregnancy from starting.
ellaOne je kontracepcijsko sredstvo, ki se uporablja za preprečevanje nastopa nosečnosti.
ellaOne is a contraceptive used to prevent a pregnancy from starting.
ellaOne je kontracepcijsko sredstvo, ki se uporablja za preprečitev nastopa nosečnosti.
ellaOne is an emergency contraceptive
Zdravilo ellaOne je nujno kontracepcijsko sredstvo
ellaOne is an emergency contraceptive that decreases pregnancy risk after unprotected intercourse but does not confer contraceptive protection for subsequent acts of intercourse.
ellaOne je nujno kontracepcijsko sredstvo, ki zmanjšuje tveganje za nosečnost po nezaščitenem spolnem odnosu, vendar ne zagotavlja kontracepcijske zaščite za nadaljnje spolne odnose.
ellaOne is for occasional use only.
Zdravilo ellaOne je namenjeno občasni uporabi.
ellaOne is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant (see section 4.2).
Zdravilo ellaOne ni namenjeno uporabi med nosečnostjo in ga ne sme vzeti nobena ženska, ki sumi ali ve, da je noseča (glejte poglavje 4.3).
ellaOne is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant.
Zdravilo ellaOne ni namenjeno za uporabo med nosečnostjo in ga ne sme vzeti nobena ženska, ki sumi ali ve, da je noseča.
ellaOne is suitable for any woman of childbearing age, including adolescents.
Zdravilo ellaOne je primerno za vse ženske v rodni dobi, vključno z mladostnicami.
ellaOne may make regular hormonal contraceptives, like pills and patches, temporarily less effective.
Zaradi zdravila ellaOne je lahko redna hormonska kontracepcija, kot so tablete in obliži, začasno manj učinkovita.
ellaOne will not affect your future fertility.
Zdravilo ellaOne ne bo vplivalo na vašo plodnost v prihodnosti.
ELLIPTA 1 inhaler of 7 doses
ELLIPTA 1 inhalator s 7 odmerki.
Elliptical, blue, coated tablets debossed with “LILLY” and a numeric identicode “4415”.
Eliptične, modre, obložene tablete z vtisnjenim napisom "LILLY" in številčno identifikacijsko oznako “4415”.
Elliptical, pink, coated tablets debossed with “LILLY” and a numeric identicode, “4420”.
Elitične, rožnate, obložene tablete z vtisnjenim napisom "LILLY" in številčno identifikacijsko oznako “4420”.
Elliptically shaped, white tablets imprinted with the code ’4165’.
Eliptično oblikovane tablete bele barve, na katerih je odtisnjena šifra ’4165’.
ELOCTA 1000 IU powder and solvent for solution for injection
ELOCTA 1000 i.e. prašek in vehikel za raztopino za injiciranje
ELOCTA 1500 IU powder and solvent for solution for injection
ELOCTA 1500 i.e. prašek in vehikel za raztopino za injiciranje
ELOCTA 2000 IU powder and solvent for solution for injection
ELOCTA 2000 i.e. prašek in vehikel za raztopino za injiciranje
ELOCTA 250 IU powder and solvent for solution for injection ELOCTA 500 IU powder and solvent for solution for injection ELOCTA 750 IU powder and solvent for solution for injection ELOCTA 1000 IU powder and solvent for solution for injection ELOCTA 1500 IU powder and solvent for solution for injection ELOCTA 2000 IU powder and solvent for solution for injection ELOCTA 3000 IU powder and solvent for solution for injection
ELOCTA 250 i.e. prašek in vehikel za raztopino za injiciranje ELOCTA 500 i.e. prašek in vehikel za raztopino za injiciranje ELOCTA 750 i.e. prašek in vehikel za raztopino za injiciranje ELOCTA 1000 i.e. prašek in vehikel za raztopino za injiciranje ELOCTA 1500 i.e. prašek in vehikel za raztopino za injiciranje ELOCTA 2000 i.e. prašek in vehikel za raztopino za injiciranje ELOCTA 3000 i.e. prašek in vehikel za raztopino za injiciranje
ELOCTA 250 IU powder for solution for injection
ELOCTA 250 i.e. prašek za raztopino za injiciranje
ELOCTA 3000 IU powder and solvent for solution for injection
ELOCTA 3000 i.e. prašek in vehikel za raztopino za injiciranje
ELOCTA 750 IU powder and solvent for solution for injection
ELOCTA 750 i.e. prašek in vehikel za raztopino za injiciranje
Elocta can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of haemophilia.
Izdaja zdravila Elocta je le na recept, zdravljenje z njim pa se sme uvesti in izvajati samo pod nadzorom zdravnika z izkušnjami z zdravljenjem hemofilije.
ELOCTA contains the active substance efmoroctocog alfa, a recombinant coagulation factor VIII, Fc fusion protein.
Zdravilo ELOCTA vsebuje zdravilno učinkovino efmoroktokog alfa, rekombinantni koagulacijski faktor VIII, fuzijsko beljakovino Fc.
ELOCTA has no influence on the ability to drive and use machines.
Zdravilo ELOCTA nima vpliva na sposobnost vožnje in upravljanja s stroji.
ELOCTA is administered by intravenous (IV) injection after dissolving the powder for injection with the solvent supplied in the pre-filled syringe.
Zdravilo ELOCTA se daje v obliki intravenske (i.v.) injekcije potem, ko se prašek za injekcijo raztopi z vehiklom v napolnjeni injekcijski brizgi.
Elonva 100 micrograms injection corifollitropin alfa
Elonva 100 mikrogramov injekcija korifolitropin alfa
Elonva 150 micrograms injection corifollitropin alfa
Elonva 150 mikrogramov injekcija korifolitropin alfa
Elonva can only be obtained with a prescription.
Izdaja zdravila Elonva je le na recept.
Elonva contains sodium
Zdravilo Elonva vsebuje natrij
Elonva contains the active ingredient corifollitropin alfa and belongs to the group of medicines called gonadotropic hormones.
Zdravilo Elonva vsebuje zdravilno učinkovino korifolitropin alfa in spada v skupino zdravil, imenovanih gonadotropni hormoni.
Elonva is a clear and colourless aqueous solution for injection (injection) in a pre-filled syringe with an automatic safety system, which prevents needle stick injuries after use.
Zdravilo Elonva je bistra in brezbarvna vodna raztopina za injiciranje (injekcija) v napolnjeni injekcijski brizgi z avtomatskim varnostnim sistemom, ki preprečuje poškodbe zaradi vboda igle.
Elonva is a solution for injection that contains the active substance corifollitropin alfa.
Zdravilo Elonva je raztopina za injiciranje, ki vsebuje zdravilno učinkovino korifolitropin alfa.
Elonva is given once as a single injection under the skin in a dose of 100 or 150 micrograms, depending on age and body weight.
Zdravilo Elonva se injicira enkrat v podkožje, in sicer kot enojna injekcija v odmerku 100 ali 150 mikrogramov, odvisno od telesne mase bolnice.
Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
Zdravilo Elonva se uporablja pri ženskah, ki se zdravijo zaradi neplodnosti, da se v jajčnikih spodbudi dozorevanje več kot enega jajčeca naenkrat.
Elonva must not be used in patients with tumours of the ovary, breast, womb, pituitary (a gland located at the base of the brain that produces FSH) or hypothalamus (a region of the brain).
Zdravila Elonva ne smejo uporabljati bolnice s tumorji jajčnikov, dojke, maternice, hipofize (žleze na možganskem dnu, ki tvori FSH) ali hipotalamusa (predela v možganih).
Elosulfase alfa is intended to provide the exogenous enzyme N-acetylgalactosamine-6-sulfatase that will be taken up into the lysosomes and increase the catabolism of the GAGs KS and C6S.
Elosulfaza alfa je namenjena proizvodnji eksogenega encima N-acetilgalaktozamin-6- sulfataza, ki preide v lizosome in povečuje razgradnjo substratov GAG, KS in C6S.
Elosulfase alfa is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce the enzyme.
Elosulfaza alfa se pridobiva z metodo, imenovano „tehnologija rekombinantne DNA“: izdelajo jo celice, v katere so vstavili gen (DNA), s pomočjo katerega lahko tvorijo ta encim.
Elotuzumab also attaches to SLAMF7 on the cancer cells, making them more vulnerable to attack by the immune cells.
Elotuzumab se pritrdi tudi na SLAMF7 na rakavih celicah, ki tako postanejo bolj ranljive, ko jih napadejo imunske celice.
Elotuzumab also targets SLAMF7 on myeloma cells and facilitates the interaction with natural killer cells to mediate the killing of myeloma cells through antibody-dependent cellular cytotoxicity (ADCC).
Elotuzumab z delovanjem na SLAMF7 na mielomskih celicah tudi pospeši interakcijo z naravnimi celicami ubijalkami in tako spodbudi uničenje mielomskih celic preko od protiteles odvisne celične citotoksičnosti (ADCC, antibody-dependent cellular cytotoxicity).
Elotuzumab is dosed via intravenous route and therefore is immediately and completely bioavailable.
Elotuzumab se uporablja intravensko, zato je njegova biološka uporabnost takojšnja in popolna.
Elotuzumab will be given in combination with lenalidomide and breast-feeding should be stopped because of the use of lenalidomide.
Elotuzumab se uporablja v kombinaciji z lenalidomidom, zato je zaradi uporabe lenalidomida treba prenehati z dojenjem.
Elotuzumab will be given in combination with lenalidomide, which is contraindicated during pregnancy.
Elotuzumab se uporablja v kombinaciji z lenalidomidom, katerega uporaba med nosečnostjo je kontraindicirana.
Eltrombopag administration can cause abnormal liver function and severe hepatotoxicity, which might be life-threatening.
Zdravljenje z eltrombopagom lahko povzroči nenormalno delovanje jeter in hudo hepatotoksičnost, ki je lahko življenjsko nevarna.
Eltrombopag did not affect female fertility, early embryonic development or embryofoetal development in rats at doses up to 20 mg/kg/day (2 times the human clinical exposure in adult or adolescent (12-17 years) ITP patients at 75 mg/day and equivalent to the human clinical exposure in HCV patients at 100 mg/day, based on AUC).
Eltrombopag pri podganah pri odmerkih do 20 mg/kg/dan (2-kratna izpostavljenost človeka pri klinični uporabi pri odraslih ali adolescentnih (starih od 12 do 17 let) bolnikih z ITP pri odmerkih 75 mg/dan in enaka izpostavljenost človeka pri klinični uporabi pri bolnikih s HCV pri odmerkih 100 mg/dan, na osnovi vrednosti AUC) ni vplival na plodnost samic, zgodnji embrionalni razvoj ali embriofetalni razvoj.
Eltrombopag dose adjustment is permitted during the course of the treatment based on the patient’s platelet count (see section 4.2).
Med zdravljenjem je dovoljeno prilagajati odmerke eltrombopaga na osnovi števila trombocitov pri bolniku (glejte poglavje 4.2).
Eltrombopag dosing requirements must be individualised based on the patient’s platelet counts.
Odmerek eltrombopaga je treba določiti na osnovi števila trombocitov pri vsakem bolniku posebej.
Eltrombopag given in combination with peginterferon alfa-2a (180 mcg once weekly for 48 weeks for genotypes 1/4/6; 24 weeks for genotype 2/3) plus ribavirin (800 to 1200 mg daily in 2 divided doses orally)
prejemanje eltrombopaga sočasno s peginterferonom alfa-2a (180 mg enkrat na teden 48 tednov za genotip 1/4/6; 24 tednov za genotip 2/3) in ribavirinom (peroralno 800 do 1200 mg na dan v dveh razdeljenih odmerkih)
Eltrombopag interacts with the transmembrane domain of the human TPO-R and initiates signalling cascades similar but not identical to that of endogenous thrombopoietin (TPO), inducing proliferation and differentiation from bone marrow progenitor cells.
Eltrombopag stopa v interakcijo s transmembransko domeno humanega TPO-R in sproži signalno kaskado, ki je podobna, ne pa tudi identična tisti pri endogenem trombopoetinu (TPO), ter tako inducira proliferacijo in diferenciacijo iz matičnih celic v kostnem mozgu.
Eltrombopag is highly bound to human plasma proteins (> 99.9%), predominantly to albumin.
Eltrombopag se v obsežni meri veže na humane plazemske proteine (> 99,9 %), predvsem na albumin.
Eltrombopag N=74
Eltrombopag N = 74
Eltrombopag should not be used in ITP patients with hepatic impairment (Child-Pugh score ≥ 5) unless the expected benefit outweighs the identified risk of portal venous thrombosis (see section 4.4).
Pri bolnikih z ITP, ki imajo okvaro jeter (ocena po Child-Pugh-u ≥ 5) se eltrombopag ne sme uporabljati, razen če pričakovana korist zdravljenja prevlada nad znanim tveganjem za pojav tromboze portalne vene (glejte poglavje 4.4).
Eltrombopag should not be used in ITP patients with hepatic impairment (Child-Pugh score ≥ 5) unless the expected benefit outweighs the identified risk of portal venous thrombosis.
Pri bolnikih z okvaro jeter (ocena po Child-Pugh-u ≥ 5) se eltrombopaga ne sme uporabljati, razen če pričakovana korist zdravljenja prevlada nad znanim tveganjem za pojav tromboze portalne vene.
Eltrombopag should not be used in patients with hepatic impairment (Child Pugh score ≥ 5) unless the expected benefit outweighs the identified risk of portal venous thrombosis.
Pri bolnikih z okvaro jeter (ocena po Child-Pughu ≥ 5) se eltrombopaga ne sme uporabljati, razen če pričakovana korist zdravljenja prevlada nad znanim tveganjem za pojav tromboze portalne vene.
Eltrombopag should not be used outside of clinical trials for the treatment of thrombocytopenia due to MDS or any other cause of thrombocytopenia other than the approved indications.
Eltrombopaga se izven kliničnih preskušanj ne sme uporabljati za zdravljenje trombocitopenije, ki je posledica MDS, ali trombocitopenije zaradi kakršnegakoli drugega vzroka razen odobrenih indikacij.
Eltrombopag should only be administered to such patients after careful consideration of the expected benefits in comparison with the risks.
Ti bolniki lahko prejemajo eltrombopag le po skrbnem premisleku o pričakovanih koristi v primerjavi z tveganji.
Eltrombopag treatment should be initiated and remain under the supervision of a physician who is experienced in the treatment of haematological diseases or the management of chronic hepatitis C and its complications.
Zdravljenje z eltrombopagom mora začeti in ostati pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem hematoloških bolezni ali kroničnih okužb s hepatitisom C in njegovih zapletov.
Eluates should only be taken from a technetium (99mTc)-generator that has been eluted within the past 24 hours (i.e. with less than 24 h in-grow).
Uporabite lahko le izpirke iz generatorja tehnecija (99mTc), ki se je izpiral v zadnjih 24 urah (tj. z manj kot 24-urnim prirastkom).
Eluxadoline has not been specifically studied in patients who have renal impairment.
Eluksadolina niso posebej preučevali pri bolnikih z okvaro ledvic.
Eluxadoline increases the exposure of the co-administered OATP1B1 substrate; rosuvastatin (see section 5.2) by up to 40% of the total exposure which is usually not considered to be clinically relevant.
Eluksadolin poveča izpostavljenost sočasno uporabljenemu substratu OATP1B1, rosuvastatinu (glejte poglavje 5.2), za do 40 % celotne izpostavljenosti, kar navadno ne šteje za klinično pomembno.
Eluxadoline is a locally acting, mixed mu opioid receptor (μOR) agonist and delta opioid receptor (δOR) antagonist.
Eluksadolin je lokalno delujoč, mešan agonist opioidnih receptorjev mi ( μOR) in antagonist opioidnih receptorjev delta (δOR).
Eluxadoline may increase the exposure of co-administered medicinal products metabolised by Cytrochrome CYP3A4.
Eluksadolin lahko poveča izpostavljenost sočasno uporabljenim zdravilom, ki jih presnavlja citokrom CYP3A4.
Eluxadoline must not be used in patients with a history of or known or suspected hepatic impairment (Child-Pugh Class A-C) (see section 4.3).
Eluksadolin se ne sme uporabljati pri bolnikih z anamnezo okvare jeter ali znano ali domnevno okvaro jeter (Child-Pugh razred A–C) (glejte poglavje 4.3).
Eluxadoline should not be restarted in patients who developed biliary duct obstruction or sphincter of Oddi spasm while taking eluxadoline (see section 4.3).
Eluksadolin se ne sme ponovno uvesti pri bolnikih, pri katerih sta se med zdravljenjem z eluksadolinom razvila zapora žolčevoda ali spazem Oddijevega sfinktra (glejte poglavje 4.3).
Eluxadoline’s systemic exposure following oral administration is low and is consistent with its local action in the GI tract.
Sistemska izpostavljenost eluksadolinu po peroralni uporabi je majhna in skladna z njegovim lokalnim delovanjem v prebavilih.
Elvitegravir (125 mg once daily)
elvitegravir (125 mg enkrat
Elvitegravir (125 mg once daily) Ritonavir (100 mg twice daily)
dnevno) ritonavir (100 mg dvakrat dnevno)
Elvitegravir (125 mg once daily) Ritonavir (100 mg twice daily)
elvitegravir (125 mg enkrat
Elvitegravir (150 mg once daily)
elvitegravir (150 mg enkrat
Elvitegravir (150 mg once daily) Cobicistat (150 mg once daily)
dnevno) kobicistat (150 mg enkrat dnevno)
Elvitegravir (150 mg once daily) Cobicistat (150 mg once daily)1
dnevno) elvitegravir (150 mg enkrat
Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)/ Emtricitabine (200 mg once daily)/ Tenofovir alafenamide (10 mg once daily)5
elvitegravir (150 mg enkrat dnevno)/kobicistat (150 mg enkrat dnevno)/emtricitabin (200 mg enkrat dnevno)/ alafenamidtenofovirat (10 mg enkrat dnevno)5
Elvitegravir (150 mg once daily)/Cobicistat (150 mg once daily)4
elvitegravir (150 mg enkrat dnevno)/kobicistat (150 mg enkrat dnevno)4
Elvitegravir (200 mg once daily)
elvitegravir (200 mg enkrat
Elvitegravir (300 mg once daily)
elvitegravir (300 mg enkrat dnevno)
Elvitegravir (50 mg once daily
elvitegravir (50 mg enkrat dnevno)
Elvitegravir (50 mg once daily)
dnevno) elvitegravir (50 mg enkrat dnevno)
Elvitegravir (50 mg once daily)
elvitegravir (50 mg enkrat dnevno)
Elvitegravir (85 mg once daily)
atazanavir (300 mg enkrat dnevno)
Elvitegravir (antacid suspension
elvitegravir (suspenzija antacida,
Elvitegravir (simultaneous
elvitegravir (sočasno dajanje z
elvitegravir administration):
elvitegravirja):
elvitegravir are not expected to
Ne pričakuje se, da bi sočasno
Elvitegravir did not show any carcinogenic potential in long-term oral carcinogenicity studies in mice and rats.
V dolgoročnih študijah peroralne kancerogenosti elvitegravir ni pokazal kancerogenega potenciala pri miših in podganah.
Elvitegravir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O (EC50 values ranged from 0.1 to 1.3 nM) and activity against HIV-2 (EC50 of 0.53 nM).
Elvitegravir je pokazal protivirusno aktivnost v celični kulturi proti podtipom A, B, C, D, E, F, G in O virusa HIV-1 (vrednosti EC50 so bile v razponu od 0,1 do 1,3 nM) in aktivnost proti HIV-2 (vrednost EC50 je bila 0,53 nM).
elvitegravir in combination with cobicistat is not recommended (see section 4.4).
Sočasno dajanje zdravila Viramune in elvitegravirja v kombinaciji s kobicistatom je odsvetovano (glejte poglavje 4.4).
Elvitegravir is 98-99% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1.0 ng/mL to 1.6 µg/mL.
Elvitegravir se 98–99 % veže na humane plazemske proteine, pri čemer vezava ni odvisna od koncentracije zdravila v razponu od 1,0 ng/ml do 1,6 µg/ml.
Elvitegravir is a type of antiviral agent called an ‘integrase inhibitor’.
Elvitegravir je vrsta protivirusne učinkovine, imenovana „zaviralec integraze‟.
Elvitegravir is a type of antiviral agent called an ‘integrase inhibitor’.
Elvitegravir je vrsta protivirusnega sredstva, imenovanega „zaviralec integraze“.
Elvitegravir plasma concentrations
Koncentracije elvitegravirja v
Elvitegravir plasma exposures are non-linear and less than dose-proportional, likely due to solubility- limited absorption.
Izpostavljenosti elvitegravirju v plazmi so nelinearne in manjše kot sorazmerne z odmerkom, verjetno zaradi absorpcije, omejene s topnostjo.
Elvitegravir undergoes oxidative metabolism by CYP3A (major route), and glucuronidation by UGT1A1/3 enzymes (minor route).
Elvitegravir se presnavlja z oksidacijo s CYP3A (glavna pot) in glukuronidacijo z encimi UGT1A1/3 (manj pomembna pot).
Elvitegravir undergoes oxidative metabolism by CYP3A (major route), and glucuronidation by UGT1A1/3 enzymes (minor route).
Elvitegravir se presnavlja z oksidacijo z CYP3A (glavna pot) in glukuronidacijo z UGT1A1/3 (manj pomembna pot).
Elvitegravir undergoes oxidative metabolism by CYP3A (major route), and glucuronidation via UGT1A1/3 enzymes (minor route).
Elvitegravir se presnavlja z oksidacijo s CYP3A (glavna pot) in glukuronidacijo z encimi UGT1A1/3 (manj pomembna pot).
elvitegravir, an antiretroviral medicine known as an integrase inhibitor
elvitegravir, protiretrovirusno zdravilo, znano kot zaviralec integraze
elvitegravir, an antiretroviral medicine known as an integrase inhibitor cobicistat, a booster (pharmacokinetic enhancer) of the effects of elvitegravir
elvitegravir, protiretrovirusno zdravilo, znano kot zaviralec integraze